The Pfizer and BioNTech mRNA Vaccine for COVID-19 Conferred 95% Protection With a Satisfactory Safety Profile
Pfizer and BioNTech release safety and efficacy data from phase 2/3 trials for their COVID-19 mRNA vaccine.
Pfizer and BioNTech release safety and efficacy data from phase 2/3 trials for their COVID-19 mRNA vaccine.
Further research is needed to identify possible interventions that may mitigate the racial disparities seen in COVID-19.
Case of a 15-year-old African American girl with COVID-19 who developed atrial fibrillation and fulminant myocarditis.
Cutaneous and histopathologic manifestations of COVID-19 infection in a pediatric population are described.
Investigators examined whether brensocatib reduces incidence of exacerbations of bronchiectasis, reduces rate of exacerbations, or changes the concentration of active neutrophil in the sputum from baseline.
Investigators assessed whether interleukin-6 inhibitors reduced the odds of in-hospital COVID-related mortality.
Researchers examined duration of viral RNA shedding and viable virus shedding of SARS-CoV-2 in body fluids and compared SARS-CoV-2, SARS-CoV, and MERS-CoV viral dynamics.
The FDA is alerting clinical laboratory staff and health care providers regarding the risk of false negative results with any SARS-CoV-2 test if a mutation occurs in the part of the virus’ genome assessed by that test.
Study researchers investigated whether the COVID-19 pandemic potentially contributed to the delay in acute stroke care.
Investigators conducted the PlasmAr trial to evaluate the safety and efficacy of convalescent plasma in the treatment of SARS-CoV-2 pneumonia.